Bradykinin (BK) is produced and acts at the site of injury and inflammation. In the CNS, migration of microglia toward the lesion site plays an important role pathologically. In the present study, we investigated the effect of BK on microglial migration. Increased motility of cultured microglia was mimicked by B 1 receptor agonists and markedly inhibited by a B 1 antagonist , but not by a B 2 receptor antagonist. BK induced chemotaxis in microglia isolated from wild-type and B 2 -knock-out mice but not from B 1 -knock-out mice. BK-induced motility was not blocked by pertussis toxin but was blocked by chelating intracellular Ca 2ϩ or by low extracellular Ca 2ϩ , implying that Ca 2ϩ influx is prerequisite. Blocking the reverse mode of Na ϩ /Ca 2ϩ exchanger (NCX) completely inhibited BK-induced migration. The involvement of NCX was further confirmed by using NCX ϩ/Ϫ mice; B 1 -agonist-induced motility and chemotaxis was decreased compared with that in NCX ϩ/ϩ mice. Activation of NCX seemed to be dependent on protein kinase C and phosphoinositide 3-kinase, and resultant activation of intermediate-conductance (IK-type) Ca 2ϩ -dependent K ϩ currents (I K(Ca) ) was activated. Despite these effects, BK did not activate microglia, as judged from OX6 staining. Using in vivo lesion models and pharmacological injection to the brain, it was shown that microglial accumulation around the lesion was also dependent on B 1 receptors and I K(Ca) . These observations support the view that BK functions as a chemoattractant by using the distinct signal pathways in the brain and, thus, attracts microglia to the lesion site in vivo.
Introduction
Activation of microglial cells, the resident macrophages of the brain, occurs rapidly after brain injury (Kreutzberg, 1996; Kim and Vellis, 2005) . Activated microglia migrate rapidly to the affected sites of the CNS. The nonapeptide, bradykinin (BK), is produced in the brain during trauma and stroke, leading to an increase in blood-brain barrier permeability and an accumulation of leukocytes, and is therefore regarded as a mediator of inflammation and vasodepression (Abbott, 2000; Lehmberg et al., 2003) . In the brain, BK has been assigned a neuroprotective role (Yasuyoshi et al., 2000; Noda et al., 2007a) , especially via BK receptors in microglia (Noda et al., 2006 (Noda et al., , 2007a . BK receptors are coupled to multiple signal transduction pathways (Hall, 1992; Noda et al., 2004) . One is mobilization of intercellular Ca 2ϩ induced by inositol 1,4,5-trisphosphate (IP 3 ) and activation of Ca 2ϩ -dependent K ϩ (K Ca ) channels (Higashida and Brown, 1988) , inducing activation of phospholipase A2 and stimulation of arachidonic acid release (Welsh et al., 1988 , Yanaga et al., 1991 . BK receptors also couple to G i/o -proteins, leading to mitogen-activated protein (MAP) kinase signal transduction (Liebmann, 2001) . In unstimulated cultured microglia, expression of both B 1 and B 2 receptors was low, but strong immunolabeling of both B 1 and B 2 receptors was observed after the treatment of the cells with BK (Noda et al., 2007a) . It was also reported that activation of BK receptors in microglia linked to activation of K Ca channels. It is now well established that microglial cells can be neuroprotective or neurodestructive depending on the pathologic context and the type of stimulation (Pocock and Kettenmann, 2007) . Our data indicate that BK triggers responses in microglia, which ultimately results in a protection of neurons, namely by inhibiting proinflammatory cytokine release and thus attenuating an inflammatory response (Noda et al., 2007a) .
Microglia are abundant in all regions of the CNS. Under pathological conditions, activated microglia can phagocytose dead cells and clear cellular debris at the site of injury (Raivich et al., 1999; Stoll and Jander, 1999; Streit et al., 1999) . There are several candidate molecules that serve as signals for pathologic events to microglia. As recently shown by Davalos et al. (2005) , microglial processes rapidly respond to ATP, and ATP has been reported to be a chemoattractant for microglial cells (Honda et al., 2001) . A variety of other signals stimulate microglial motility, such as cannabinoids (Walter et al., 2003) , morphine (Takayama and Ueda., 2005) , or the chemokine CCL21 (Rappert et al., 2002) . Neuropeptides including BK are another family of candidates (Palkovits, 1995) .
In the present study, we investigated the BK-induced increase in microglial migration and its underlying signaling cascade. The results indicate that BK can attract microglia to a lesion or inflammation sites, where BK is known to be upregulated, because it is a chemoattractant and increases microglial motility.
Materials and Methods
Cell culture. The study was approved by the Animal Research Committee of Kyushu University and Max-Delbrück Center for Molecular Medicine and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Rat microglial cells were isolated from mixed cultures of cerebrocortical cells in postnatal day 3 Wistar rats (Kyudo, Kumamoto, Japan) as described previously (Noda et al., 2003) . In brief, for rat microglia, the cerebral cortex was minced and treated twice with papain (90 U) and DNase (2000 U) at 37°C for 15 min. Dissociated cells were seeded into 300 cm 2 plastic flasks at a density of 10 7 per 300 cm 2 in Eagle's medium (MEM) with 0.17% NaHCO 3 and 10% fetal calf serum (FCS) and maintained at 37°C in 10% CO 2 /90% air. Medium was changed twice per week. After 10 -14 d, floating cells and weakly attached cells on the mixed primary cultured cell layer were obtained by gently shaking for 5-8 min. Microglial cells were then isolated as strongly adhering cells after unattached cells were removed. The purity of the microglial culture ranged from 95 to 99%, which was evaluated by staining with Griffonia simplicifolia isolectin B4, a marker for microglia.
Mouse microglial cells were isolated from total brain of newborn B 1 receptor-knock-out (KO) (Pesquero et al., 2000) , B 2 receptor-knock-out (Milia et al., 2001) , and wild-type control mice (C57BL/6J) as described previously (Prinz et al., 1999) . In brief, cortical tissue was trypsinized for 2 min, dissociated with a fire-polished pipette, and washed twice. Mixed glial cells were cultured for 9 -12 d in DMEM supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin, with medium changes every third day. Microglial cells were then separated from the underlying astrocytic layer by gentle shaking of the flask for 1 h at 37°C in a shaker-incubator (100 rpm). The purity of microglia was Ͼ95%. Cells were used for experiments 1-5 d after plating. Cell media and supplements were purchased from Seromed/Biochrom (Berlin, Germany).
Motility experiment. Rat cultured microglia were seeded on glassbottom dishes (Matsunami, Osaka, Japan) at a density of 10 4 cells per dish. Motility of microglia under the control of temperature (37°C) and gas (10% CO 2 /90% air) was monitored with a time-lapse video microscopy system (Nikon Instec, Fukuoka, Japan). The video camera (Nikon inverted microscope, TE-2000-E) was controlled by Luminavision software (Mitani, Osaka, Japan). Images were acquired in 1 min intervals for 1 h and stored on a computer and analyzed by Dipp-Motion 2D (Ditect, Tokyo, Japan). Cell motility in response to BK and other chemicals was assessed by adding stock solution to the dish, diluting 100 times to get the final concentration. The diffusion of the drugs within the dish occurred rapidly and had distributed before the first image was taken, as verified by adding a dye.
Microchemotaxis assay. BK-induced chemotaxis was tested using a 48-well microchemotaxis Boyden chamber (Neuroprobe, Bethesda, MD) (Nolte et al., 1997) . Upper and lower wells were separated by polycarbonate filter (8 m pore size; Poretics, Livermore, CA). Microglial cells (2-4 ϫ 10 4 ) in 50 l of serum-free MEM or DMEM medium were added to the upper wells, and the lower wells contained medium containing BK with or without other drugs. Culture medium (MEM or DMEM) was used as a control. The chamber was incubated at 37°C and 5% CO 2 for 180 min. Cells remaining on the upper surface of the membrane were removed by wiping, and migrated cells were subjected to Diff-Quik stain (Sysmex, Kobe, Japan). The rate of microglial migration was calculated by counting cells in four random fields of each well using a 40ϫ brightfield objective. The number of cells was ϳ50 -80 cells per field in control condition, and the number of fields in each condition was 92-152 (23-38 wells). The number of cells in each field was normalized to the average in control condition (100%). Immunocytochemical analysis. Rat primary cultured microglia were fixed with 4% paraformaldehyde, treated with a primary antibody against activated microglia, OX6 (1:250) (PharMingen, San Diego, CA) together with goat serum (10% in volume) for overnight at room temperature, washed four times, and then incubated with the Alexa Fluor 594-conjugated goat anti-mouse (1:200) antibody (Invitrogen, Carlsbad, CA) together with goat serum (10% in volume) at room temperature for 6 h. Series of images were examined with a confocal laser-scanning microscope (LSM510; Carl Zeiss, Oberkochen, Germany). The fluorescence intensity was measured by Photoshop (Adobe Systems, San Jose, CA).
Lesion model mice. Male C57BL/6 mice (8 -12 weeks old) and BK 1 and BK 2 receptor-knock-out mice (8 -12 weeks) were anesthetized with pentobarbital (12.5 mg/kg) and placed in a stereotactic apparatus. A 2-l Hamilton syringe with a 26 or 23 gauge needle was inserted into the right cortex through a small hole drilled through the skull. For cortex lesion, the microsyringe was inserted into brains of knock-out or wild-type mice at the following coordinates; anterior, 1 mm; lateral, 2.2 mm; and dorsoventral, 4 mm. For injection of charybdotoxin (CTX) (0.1 M) or PBS (both in 1 l volume) in C6BL/6J mice (Kyudo, Saga, Japan), the needle was lifted for 1 mm. n ϭ 3-4 animals were used per experimental group. Eighteen hours after making lesion by insertion of microsyringe or microinjection of CTX or PBS, each mouse was anesthetized with pentobarbital (12.5 mg/kg) and transcardially perfused with 20 ml each of 10 U/ml heparin and 0.5% procaine in PBS and 4% paraformaldehyde. Then the brain was removed, postfixed for 3 h, and cryoprotected for 24 h in PBS containing 20% sucrose and 0.05% sodium azide.
Immunofluorescent labeling with microglia. The brain was sliced into 20 m in thickness using a cryostat, and the sections were placed on a slide glass precoated with silane and stored at Ϫ80°C until the time to use. The coronal sections were cut from part of the cortex. The sections were permeabilized with 0.3% Triton X-100 (Sigma, St. Louis, MO) in PBS for 15 min and blocked in PBS containing 1% BSA and 5% normal donkey serum (Jackson ImmunoResearch, West Grove, PA) for 60 min at room temperature. The brain sections were incubated overnight at 4°C with primary antibody, rabbit anti-Iba1 antibody (1:500; Wako, Richmond, VA), and incubated for 5 h with Alexa Fluor 488 goat anti-rabbit IgG (1:250; Invitrogen) at room temperature. Every treatment was followed by washing three times for 5 min with PBS. Sections were mounted in the Permafluor aqueous mounting medium (Thermo Fisher Scientific, Waltham, MA) and were analyzed with a confocal laser-scanning microscope (LSM510 Meta; Carl Zeiss). Quantification of microglia number around the lesion site. Microglia in the sections containing lesion were immunohistochemically stained with anti-Iba-1 as mentioned above. The number of microglia in 60 -80 areas of 100 ϫ 100 m around the lesion site in five slices per brain was counted, and the averaged number per 10 4 m 2 for each brain was obtained.
Statistical analysis. The results are expressed as the mean Ϯ SEM. The data were compared with Student's t test or one-way ANOVA followed by the Scheffé or Dunnett's test, using software package Statview 5.0J. Values of p Ͻ 0.05 were considered statistically significant.
Drugs and reagents. BK was from Peptide Institute (Osaka, Japan) or Sigma. ATP, Griffonia simplicifolia isolectin B4 3Ј, and 4Ј-dichlorobenzamil hydrochloride were from Sigma. Charybdotoxin, iberiotoxin, apamin, staurosporine, wortmannin, chelerythrine chloride, and PD98059 (2Ј-amino-3Ј-methoxyflavone) were from Sigma. DesArg 9 -[Leu 8 ]-bradykinin, Hoe140, Des-Arg 9 -bradykinin, and DesArg 10 -kallidin were from Peptide Institute (Osaka, Japan). Pertussis toxin (PTX) was from List Biological Laboratories (Campbell, CA). KB-R7943 (2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea, methane sulfonate) was from EMD Biosciences (San Diego, CA). Gadolinium oxide was from Ishizu Seiyaku (Osaka, Japan). SN-6 was provided by Senju Pharmaceutical (Kobe, Japan).
Results

Bradykinin-induced motility of microglia is mediated by B 1 receptors but not by B 2 receptors
To examine the motility of microglia, individual cells were monitored by time-lapse video microscopy for 1 h. Figure 1 A shows images of cultured microglial cells at 0, 30, and 60 min after addition of 300 nM BK. A significant increase in microglial motility was observed already after 15 min (data not shown). The increase in microglial motility could be monitored for up to 18 h (data not shown). The average distance of microglial migration determined within 1 h increased significantly in the presence of BK. However, there was no significant difference between 100, 300, and 1000 nM BK (Fig. 1 B) .
To determine the type of BK receptor mediating BK-induced microglial motility, we tested the effect of selective antagonists for B 1 and B 2 receptor on BK-induced motility. Figure 1 , C and D, shows the effects of Des-Arg 9 -[Leu 8 ]-bradykinin, a B 1 receptor antagonist, and Hoe140, a B 2 receptor antagonist, on the BK-induced increase in microglial motility. BK-induced microglial motility was decreased by ϳ70% by the B 1 antagonist (Fig. 1C) , but was not affected by the B 2 antagonist (Fig. 1 D) . This represents that BK-induced microglial motility was caused by the activation of B 1 receptors.
Consistent with the previous results, two B 1 agonists, Des-Arg 9 -bradykinin and Des-Arg 10 -kallidin, mimicked the response of BK (Fig. 1 E, F ) . These results indicate that B 1 receptors, but not B 2 receptors, are responsible for BK-induced increase in microglial motility.
BK-induced microglial chemotaxis in B 2 -but not B 1 -knock-out mice
To confirm the pharmacological data, we used B 1 and B 2 receptor-KO mice and studied the BK-induced chemotaxis of microglia using a microchemotaxis (Boyden) chamber. In wild-type mice, BK at concentrations of 100 and 300 nM significantly increased microglial migration. The relative increases in migration by 100 and 300 nM BK were 134 Ϯ 1.89% (n ϭ 152) and 124 Ϯ 1.99% (n ϭ 148), respectively ( Fig. 2A) .
In B 1 -KO mice, 100 and 300 nM BK did not increase microglial migration (Fig.  2 B) . In contrast, in B 2 -KO mice, microglial migration induced by BK was similar to that in wild-type mice. BK increased cell migration to 118 Ϯ 4.12% (n ϭ 96) and 140 Ϯ 3.26% (n ϭ 92) with 100 and 300 nM BK, respectively (Fig. 2C) .
G i/o -protein was not involved in BKinduced microglial motility
The ATP-increased microglial migration via P2Y 12 receptor is coupled to a PTXsensitive G i/o -protein (Honda et al., 2001) . BK receptors have also been reported to couple to G i/o -protein, leading to MAP kinase signaling (Liebmann, 2001 ). Therefore, we investigated whether G i/o -protein was involved in BK-induced increase in microglial motility. As a positive control, the ATP-induced increase in microglial motility could be completely inhibited by pretreatment with PTX for 12 h (Fig. 3A) , as reported previously (Honda et al., 2001) . In contrast, pretreatment with PTX for 12 h did not affect the BK-induced increase in microglial motility (Fig. 3B) . These results suggest that PTX-sensitive G-proteins (G i/o ) are not involved in the BK-induced increase in microglial motility. ] o ϭ 0), total distance (in micrometers) of microglial migration was not affected by BK (300 nM)(n ϭ 19), Des-Arg 9 -bradykinin (300 nM)(n ϭ 18), or Des-Arg 10 -kallidin (300 nM)(n ϭ 18). C, BK-induced increase in microglial motility was inhibited by CTX (0.1 M). D, ATP (50 M)-induced microglial motility was not affected by CTX (0.1 M). E, Iberiotoxin (IBX) and apamin (APA), LK-type (large-conductance) and SK-type (smallconductance) I K(Ca) blockers, respectively, had no effect on BK-induced microglial motility. ***p Ͻ 0.001; ### p Ͻ 0.001. PKC and PI3K but not MAP/ERK signaling were involved in BK-induced microglial motility BK receptors were reported to couple to G q/11 protein and its downstream contains several protein kinases such as protein kinase C (PKC) (Higashida and Brown, 1988) and phosphoinositide 3-kinase (PI3K). The PKC inhibitors, staurosporine and chelerythrine, inhibited the increase in BK-induced microglial motility (Fig. 3C,D) . BK-induced microglial motility was partially inhibited by wortmannin, a PI3K inhibitor (Fig. 3C ), suggesting that PI3K was also involved in the increase in microglial migration induced by BK. On the other hand, BK-induced microglial motility was not affected by PD98059, a MAP kinase/extracellular signalregulated kinase (ERK) inhibitor (Fig.  3D) . These results suggested that PKCinduced phosphorylation and PI3K were important for BK-induced microglial motility.
Intracellular and extracellular Ca
2؉
were important for BK-induced microglial migration Microglial motility in the presence of BK was significantly inhibited when the cells were preincubated with 10 M BAPTA-AM, an intracellular Ca 2ϩ chelator (Fig.  4 A) . In nominally free extracellular Ca 2ϩ solution, the basal level of microglial motility was reduced and was no longer affected by either BK or the B 1 agonists DesArg 9 -bradykinin (300 nM) and DesArg 10 -kallidin (300 nM) (Fig. 4 B) . These results indicate that Ca 2ϩ influx and the subsequent increase in intracellular Ca 2ϩ are necessary for BK-induced microglial migration.
Activation of intermediate-conductance Ca
2؉ -activated K ؉ channels was involved in BK-induced microglial motility As an effector for downstream signaling by increased intracellular Ca 2ϩ , activation of Ca 2ϩ -dependent K ϩ channels was tested using specific channel blockers. In the presence of 0.1 M CTX, a blocker of Ca 2ϩ -dependent K ϩ currents (I K(Ca) ), BK did not increase microglial motility (Fig.  4C ). This result suggests that activation of I K(Ca) is required for BK-induced increase in microglial motility. In contrast, ATPinduced microglial motility was not affected by CTX (Fig. 4 D) .
Because CTX is a blocker for both intermediate-conductance (IK-type) and large-conductance (LK-type) I K(Ca) , we used a specific blocker for the LK-type, iberiotoxin, and, in addition, a specific blocker for small-conductance (SK-type) I K(Ca) , apamin. Figure 4 E shows that BKinduced microglial motility was not affected by iberiotoxin nor apamin. These results suggest that the IK-type I K(Ca) is probably responsible for BK-induced microglial migration. (Quednau et al., 1997; He et al., 1998) , and microglia (Nagano et al., 2004) . In pathological conditions such as interferon-␥ (IFN-␥) or nitric oxide exposure, the activity and expression of NCX increased in microglia, causing Na ϩ -dependent Ca 2ϩ uptake (Matsuda et al., 2006) . These results imply that NCX-induced Ca 2ϩ influx plays a key role in microglial function.
Reverse
To examine whether Ca 2ϩ influx via NCX is involved in BKinduced microglial motility, we used two benzyloxyphenyl inhibitors, KB-R7943 and SN-6, specific inhibitors of NCX in reverse mode (Iwamoto et al., 1996a (Iwamoto et al., , 2004 . BK-induced microglial motility was completely inhibited by 30 and 50 M KB-R7943 (Fig.  5B) . On the other hand, BK-induced microglial motility was not affected by gadolinium (Gd 3ϩ ), an inhibitor of capacitative calcium entry channels (Fig. 5A) . Furthermore, we used SN-6, a specific NCX inhibitor, more than KB-R7943 (Iwamoto, 2004) . Des-Arg 9 -BK (B 1 agonist)-induced microglial motility completely inhibited by 5 and 10 M SN-6 (Fig. 5C ). Next, we used heterozygous NCX knock-out mice (NCX ϩ/Ϫ ), because the homozygous (NCX Ϫ/Ϫ ) deletion is lethal (Wakimoto et al., 2000) . Using NCX ϩ/Ϫ mice, 300 nM Des-Arg 9 -BK-induced microglial motility was significantly attenuated compared with the one from wild-type (NCX ϩ/ϩ ) mice. On the other hand, ATP-induced microglial motility showed no difference between wild-type and NCX ϩ/Ϫ mice (Fig. 5D ). These results suggest that Ca 2ϩ influx via NCX is prerequisite for BK-and B 1 agonist-induced microglial motility.
We also tested the involvement of NCX and activation of I K(Ca) in BK-and B 1 agonist-induced chemotaxis using the Boyden chamber. Another NCX inhibitor, 3Ј,4Ј-dichlorobenzamil (DCB) (Plasman et al., 1991 , Krasznai et al., 2006 , inhibited BK-induced chemotaxis at concentrations of 10 and 20 M, to the control level (Fig. 6 A) . DCB alone did not affect the microglial chemotaxis.
The importance of activation of I K(Ca) was also confirmed in BK-induced chemotaxis. B 1 agonists, Des-Arg 9 -bradykinin (300 nM) and 300 nM Des-Arg 10 -kallidin, increased chemotaxis in cultured rat microglia by 177 Ϯ 8.41% (n ϭ 16) and 152 Ϯ 6.76% (n ϭ 16), respectively. These increases in chemotaxis were completely blocked by 0.1 M CTX (Fig. 6 B) .
Furthermore, we used NCX ϩ/Ϫ mice and SN-6 in chemotaxis. Des-Arg 9 -BK-induced microglial chemotaxis was completely inhibited by 5 and 10 M SN-6 (Fig. 6C) . In wild-type mice, microglial chemotaxis induced by Des-Arg 9 -BK was similar to that in cultured rat microglia. In contrast, in NCX ϩ/Ϫ mice, 300 nM Des-Arg 9 -BK did not induce microglial chemotaxis (Fig. 6 D) . Des-Arg 9 -BK-induced microglial chemotaxis was almost the same as the control level when Des-Arg 9 -BK was added to both sides of the membrane (lower and upper well) to eliminate the concentration gradient (no gradient).
Signal cascade from B 1 receptor in microglia
The above in vitro experiments using cultured microglia suggest the signaling cascade for BK-induced microglial migration shown in Figure 7 . Thus, BK (B 2 agonist) is enzymatically metabolized to B 1 agonist by kininogen, which in turn, working on B 1 receptors, coupled to G q/11 proteins, activates PKC and PI3K, phosphorylates and activates NCX, inducing influx of extracellular Ca 2ϩ , activates I K(Ca) , and then induces microglial migration by hyperpolarization or some other mechanisms.
Bradykinin did not induce OX6 expression in microglia
Activated microglia are known to express the class 2 major histocompatibility complex (MHC-2). MHC-2 expression as determined by OX6 immunoreactivity was used as indicator for microglial activation (Majed et al., 2006) . As a positive control, microglial cells were treated with IFN-␥ (50 U/ml) and ATP (50 M) (Fig. 8 A) . The fluorescence intensity of OX6 was significantly increased by IFN-␥ and ATP, but not by BK (Fig. 8 B) This indicates that BK did not induce microglial activation. We also tested the involvement of Rho and cyclic adenosine- ribose(cADPR), but they were not involved (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material).
Bradykinin acts as an inducer of microglial migration in vivo
It is important to know whether the phenomena described above occur in vivo, i.e., whether BK produced at the site of injury attracts microglia for either neuroprotection or cleaning up debris. Therefore, we compared microglial density 18 h after a focal stab wound injury in normal and B 1 -and B 2 -deficient adult mice ( Fig. 9A-C) . Because BK is not the only mediator produced at the lesion site, BK-induced microglial accumulation would be only partial. Nonetheless, microglial accumulation in B 1 -knock-out mice was significantly decreased compared with that in wild-type mice. In wild-type mice, the average microglial density at the lesion site was 14.43 Ϯ 0.69 (n ϭ 3) in the 10 4 m 2 inspected areas, whereas in the same region at the contralateral side, it was 2.73 Ϯ 0.17. In B 1 -knock-out mice, microglial accumulation was significantly decreased (11.03 Ϯ 0.35, n ϭ 4) compared with wild-type mice (Fig. 9G) . Microglial density at the contralateral side was 2.19 Ϯ 0.21 in the B 1 -knock-out mice. In B 2 -knock-out mice, microglial density was 12.83 Ϯ 0.40 at the lesion site and 2.29 Ϯ 0.28 at the contralateral side (n ϭ 3).
We also examined whether blocking the downstream components of BK-induced signal transduction also inhibited the microglial migration. Injection of CTX (0.1 M, 1 l) significantly inhibited microglial migration to the lesion site compared with that in control (injection of PBS) (Fig. 9 D, E) . The average numbers of microglia around the lesion in PBS and CTX-injected brain were 14.62 Ϯ 0.63 (n ϭ 3) and 10.62 Ϯ 0.60 (n ϭ 3) per 10 4 m 2 , respectively (Fig. 9G) , indicating that CTX impairs the accumulation at the lesion site. At the contralateral side (Fig.  9F ) , microglial density was 2.13 Ϯ 0.19 in CTX-injected and 2.23 Ϯ 0.16 in PBSinjected animals.
Discussion
Bradykinin induced microglial migration by stimulating B 1 receptors In the brain, BK receptors are expressed in all major cell types, neurons (Delmas et al., 2002) , astrocytes, oligodendrocytes (Ritchie et al., 1987; Gimpl et al., 1992; Hosli et al., 1992; Lin and Chuang, 1992; Stephens et al., 1993) , and microglial cells (Noda et al., 2003) . Two subtypes of BK receptors have been distinguished, termed B 1 and B 2 receptors. B 1 receptor mRNA is expressed at very low levels in microglia under normal conditions, but is upregulated after application of BK (Noda et al., 2003 (Noda et al., , 2007a . In the present study, we provide evidence that the BK-induced migration, both motility and chemotaxis, is mediated by B 1 , but not by B 2 receptors, because the response can be mimicked with B 1 -specific agonists and blocked by B 1 -specific antagonists. This was supported by results obtained using B 1 -and B 2 -deficient mouse lines. Combined with a chemotactic response, a general increase in motility will result in a faster accumulation of the cells at the lesion site.
The signal cascade of B 1 receptor activation
We have obtained evidence that BK would be produced after lesion in vivo and identified several steps in the intracellular signaling cascade followed by B 1 receptor activation in vitro, as shown in Figure 7 . The first step is the production of BK or kallidin at the lesion site. These are rapidly degraded by peptidases known as kininases, because the half-life of BK is reported to be Ͻ30 s in plasma (Kariya et al., 1982) . The degraded BK becomes B 1 agonist and activates the B 1 receptor linked to a PTXindependent G-protein, presumably G q/11 . Activation of members of the G q/11 family is involved in phosphoinositide (PI) turnover and the mobilization of intracellular Ca 2ϩ (Noda et al., 2004) . Although BK triggered a transient increase in intracellular Ca 2ϩ (Noda et al., 2007b ) and a transient activation of Ca 2ϩ -dependent K ϩ currents (I K(Ca) ) in microglia (Noda et al., 2003) , some observations indicate that the long-term effect of BK on migration is caused by a different signaling mechanism. This is based on the observations that (1) the population of cells showing the transient (IP 3 -induced) increase in intracellular Ca 2ϩ or I K(Ca) were ϳ20%, whereas Ͼ80% of microglial cells showed BK-induced migration; and (2) BK-induced migration depends on extracellular Ca 2ϩ levels (Fig. 4) . Our data indicate that reverse-mode operation of NCX provides the influx of Ca 2ϩ . This Ca 2ϩ influx would in turn induce a more persistent activation of I K(Ca) . Persistent I K(Ca) activation appears to be an important step in stimulating migration, because blocking I K(Ca) completely inhibited BK-induced migration (Figs. 4, 6 B) . A similar observation was reported for lysophos- phatidic acid-induced microglial migration: it also depended on the activity of intermediate-conductance I K(Ca) (Schilling et al., 2002; Eder, 2005) . One possibility is that the hyperpolarization induced by I K(Ca) increases the driving force (the electrochemical gradient) for Ca 2ϩ influx and thus enhances the intracellular Ca 2ϩ signal required to stimulate cell migration. We found that activation of the kinases PKC and PI3K are important in mediating the effects of bradykinin. This may be attributed to phosphorylation of NCX, because PKC can phosphorylate NCX, and most, but not all, studies have reported PKC-mediated increase in NCX activity (Vigne et al., 1988; Iwamoto et al., 1996b) . The involvement of PKC and tyrosine kinase in controlling NCX activity in microglia has previously been reported by Matsuda et al. (2006) . PI3K is also involved in reverse mode of NCX activity, as observed in neonatal cardiomyocytes (McDowell et al., 2004) . Because activation of PKC and PI3K could be also a downstream consequence of PI turnover, our results suggest that B 1 -induced activation of PKC, and presumably also PI3K, was linked to activation of NCX in microglia.
Distinct mechanisms of microglial migration induced by BK and ATP
Our data showed that microglial migration induced by BK and that induced by ATP were caused by different mechanisms. BKand lysophosphatidic acid-induced migration was controlled by a G i/o -protein-independent pathway, leading to an activation of I K(Ca) , whereas ATP-induced migration was via a G i/o -proteindependent but not I K(Ca) -dependent pathway. Another difference between ATP and BK was that BK did not significantly induce membrane ruffling in microglia (data not shown), as observed with ATP (Honda et al., 2001) . Furthermore, ATP and IFN-␥, but not BK, increased the expression of OX6 (Fig. 8) , a parameter of microglial activation. These differences indicate that ATP and BK control distinct microglial functions in pathological conditions such as lesion and inflammation.
New signaling by bradykinin in microglia BK is widely accepted as a signaling substance that mediates pain and inflammation, whereas the role of BK in the normal, healthy CNS still remains unknown. Recently, a neuroprotective role for BK after a neurotoxic insult has been reported (Yasuyoshi et al., 2000; Noda et al., 2007a) . Because microglial cells are the primary immune effector cells in the brain and highly dynamic surveillants of brain parenchyma (Nimmerjahn et al., 2005) , BK would be an important mediator to attract microglial cells to the site of lesion. Interestingly, the link between bradykinin and microglial migration is mediated by B 1 but not by B 2 receptors. B 1 receptors are upregulated in microglia in response to activation [e.g. by lipopolysaccharide (LPS)]. A similar upregulation of B 1 receptor subtype was observed in other cells treated with LPS, cytokine, heat stress, or endotoxin (Galizzi et al., 1994; Campos et al., 1996; Nicolau et al., 1996; Lagneux and Ribuot, 1997; Busser et al., 1998; Schremmer-Danninger et al., 1998; Wille et al., 2001 ). Another interesting observation was the involvement of NCX operating in reverse mode leading to Ca 2ϩ influx. Although the physiological function of NCX is assumed to be Ca 2ϩ extrusion, Matsuda et al. (2006) provide evidence that Ca 2ϩ uptake via NCX operating in reverse mode may play a role for microglial function under pathological conditions. The signaling cascade of BK and its coupling to NCX might be quite distinct in microglia compared with other cell types. Our results indicate that BK is an important signaling substance that affects microglial functions via activation of B 1 receptors. This information could contribute to the treatments against infectious diseases, inflammation, trauma, or neurodegeneration accompanying inflammation.
